Message from the CEO
Sustainability matters a great deal to everyone at Centrient Pharmaceuticals, and to me personally. As incoming CEO, I am proud to find myself leading an organisation driven by its purpose to deliver life-saving medicine for customers and for the good of patients worldwide.
There are many achievements I could mention from 2018 and 2019. We hit the vast majority of our environmental targets for 2020. We also strengthened our position as a leader in the sustainable production and supply of antibiotics, and as a front-runner in the fight against AMR. I can also proudly report that our semi-synthetic penicillin (SSP) active pharmaceutical ingredients (API) product range met the stringent Predicted No-Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance.
In 2018 and 2019, we strengthened our position as a leader in the sustainable production and supply of antibiotics.
Meanwhile, we took steps to strengthen and standardise our approach to sustainability worldwide, including through our recent materiality analysis. We have identified our stakeholders’ priorities regarding health and the environment. These ‘priority topics’ will provide the framework for our Sustainability Strategy going forward. So too, the GRI Standards, which are now embedded in our reporting process.
Like everyone at Centrient, I recognise we have further to go to achieve our sustainability ambitions. But I have every confidence in our organisation. I am looking forward to leading Centrient Pharmaceuticals on this journey and invite you to support us in this important mission.
Chief Executive Officer at Centrient Pharmaceuticals
Our mission is to improve lives by being at the centre of sustainable and accessible healthcare
In 2019, we unveiled the Centrient Pharmaceuticals organisational mission, vision and values.
Our mission is to improve lives by being at the centre of sustainable and accessible healthcare. Every day, we improve and save lives. All while playing a central role in modern healthcare.
Our products are indispensable, even for minor surgery treatments. Not only do we manufacture these in the most environmentally friendly and sustainable way possible, but we also take care that no antimicrobial activity is left behind in wastewater. This makes us a large contributor to the fight against antimicrobial resistance (AMR), one of the greatest health threats to mankind.
To us, ‘accessibility’ means we strive to make our products available to everyone around the globe, in all countries and all regions. This is hugely important since these medicines improve and save lives, every day. We are the market leader in all our molecules.
Our materiality topics
Our Sustainability Strategy is supported by our recent materiality assessment. The assessment defined six ‘priority topics’ with regard to sustainability, which form the central pillars of our 2019 Sustainability Report:
We advocate for responsible antibiotics manufacturing and usage, starting with our own operations.
We aim to reduce water consumption and improve our impact on the environment.
We can help improve quality of life, by making sure vital medicines are accessible to those who need them.
We are dedicated to innovative technology and to the pursuit of sustainable growth.
We strive to improve our impact on the planet by becoming more energy- and carbon-efficient.
We work hard to ensure a responsible supply chain – and demand the same commitment from our suppliers and partners.